International Clinical Trial: TeriFort 1+ Study: Efficacy and Safety of an Extensively Hydrolyzed Formula in the Management of Cow's Milk Protein Allergy in Young Children: A Prospective, Single-Arm Interventional Study (TeriFort 1+)

Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07855796) titled 'TeriFort 1+ Study: Efficacy and Safety of an Extensively Hydrolyzed Formula in the Management of Cow's Milk Protein Allergy in Young Children: A Prospective, Single-Arm Interventional Study (TeriFort 1+)' on Sept. 28.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Shanghai Teyi Yinuo Health Technology Co., Ltd.

Condition: Cow's Milk Protein Allergy (CMPA)

Intervention: Other: Diagnosed with or highly suspected CMPA: Extensively Hydrolyzed Formula intervention

Recruitment Status: Not r...